Derivation of a Novel CIHI in Patients with Lung Adenocarcinoma for Estimating Tumor Microenvironment and Clinical Prognosis

<div>Validation of CIHI in ICI treatment cohort. (a) Kaplan-Meier survival analysis of anti-PD-L1 cohort. (b) ROC analysis of 1, 3, and 5 years in anti-PD-L1 cohort. (c) Difference of CIHI in different treatment response groups. (d) Comparison of <span class="nowrap"><svg height="8.8423pt" id="M29" style="vertical-align:-0.2064009pt" version="1.1" viewbox="-0.0498162 -8.6359 8.8162 8.8423" width="8.8162pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M645 631C614 643 545 666 457 666C215 666 23 519 23 283C23 90 158 -16 337 -16C412 -16 489 2 522 10C543 39 590 127 606 167L580 181C519 89 459 18 348 18C201 18 122 136 122 287C122 464 244 632 435 632C544 632 602 595 608 472L639 475C643 526 645 581 645 631Z"></path></g></svg>-</span>index of different risk signatures. (e) Kaplan-Meier survival analysis about Liu and Liu2 signature.</div>

Disease Markers

fig9

Figure 9

Figure 9: Derivation of a Novel CIHI in Patients with Lung Adenocarcinoma for Estimating Tumor Microenvironment and Clinical Prognosis 